Medigene AG (ETR:MDG1 – Get Free Report)’s stock price rose 1.4% during trading on Tuesday . The company traded as high as €1.10 ($1.13) and last traded at €1.02 ($1.05). Approximately 27,090 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 306,207 shares. The stock had previously closed at €1.01 ($1.04).
Medigene Price Performance
The company has a current ratio of 2.39, a quick ratio of 5.85 and a debt-to-equity ratio of 12.94. The business’s fifty day moving average is €1.30 and its 200 day moving average is €1.44. The company has a market cap of $15.59 million, a P/E ratio of -0.87, a PEG ratio of 7.12 and a beta of 0.84.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Featured Articles
- Five stocks we like better than Medigene
- What Do S&P 500 Stocks Tell Investors About the Market?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Dividend Payout Ratio Calculator
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What Does Downgrade Mean in Investing?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
